PHOTON MIGRATION OF LOCALLY ADVANCED BREAST CANCER IMPACT OF NEOADJUVANT THERAP

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。新辅助化疗可以降低肿瘤分期，并使部分患者保留乳房。临床评估对化疗的反应。虽然这已被证明与改善无病生存有关，但尚不清楚原发肿瘤的临床评估是否能准确反映病理反应。UCSF乳腺中心（N. Hylton和L. Esserman）正在使用MRI来评估新辅助化疗后肿瘤大小和分布的变化。初步结果表明，MRI测量的肿瘤变化优于临床检查，是有意义的生存预测指标。MRI信号来源与肿瘤部位血容量分数、灌注、空间范围的变化有关。这些正是手持式FDPM光学探头可以在一次非侵入性测量中提供的功能参数。因此，我们将启动一项对10名UCSF患者进行检查的试点研究。每位患者将在加州大学旧金山分校接受基线MRI扫描，随后在加州大学洛杉矶分校接受光学扫描。每个化疗周期（AC、阿霉素/环磷酰胺）后进行后续MRI扫描。为了尽量减少去尔湾的次数，第二次也是最后一次光学扫描将在手术前完成，就在第四个AC周期之后。由于光学和MRI提供了互补的功能信息，我们相信这些结果将为这些疗法的机制提供有价值的见解，并有助于建立预测药物疗效的实用标准

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neoadjuvant chemotherapy can achieve tumor downstaging and allow breast conservation in some patients. Response to chemotherapy is assessed clinically. Although this has been shown to be associated with improved disease-free survival, it is not clear whether clinical assessment of the primary tumor accurately reflects pathologic response. The UCSF Breast Center (N. Hylton and L. Esserman) are using MRI to assess changes in tumor size and distribution in response to neoadjuvant chemotherapy. Preliminary results indicate that tumor changes measured by MRI are better than clinical exam and are meaningful predictors of survival. The MRI signal origin is related to changes in blood volume fraction, perfusion, and spatial extent of the tumor site. These are precisely the functional parameters that the hand-held FDPM optical probe can provide in a single, non-invasive measurement. As a result, we will initiate a pilot study that examines 10 UCSF patients. Each patient will receive baseline MRI scans at UCSF, followed by optical scans at UCI. Subsequent MRI scans will be performed following each cycle of chemotherapy (AC, Adriamycin/Cyclophosphamide). In order to minimize the number of trips to Irvine, a second and final optical scan will be completed following the 4th AC cycle, just prior to surgery. Because optical and MRI provide complementary functional information, we believe these results will provide valuable insight into the mechanisms these therapies as well as help establish practical criteria for predicting drug efficacy